[go: up one dir, main page]

SG10201900041VA - Meningococcus vaccines - Google Patents

Meningococcus vaccines

Info

Publication number
SG10201900041VA
SG10201900041VA SG10201900041VA SG10201900041VA SG10201900041VA SG 10201900041V A SG10201900041V A SG 10201900041VA SG 10201900041V A SG10201900041V A SG 10201900041VA SG 10201900041V A SG10201900041V A SG 10201900041VA SG 10201900041V A SG10201900041V A SG 10201900041VA
Authority
SG
Singapore
Prior art keywords
vaccines
meningococcus
meningococcus vaccines
fhbp
diversity
Prior art date
Application number
SG10201900041VA
Inventor
Alessia Biolchi
Brunella Brunelli
Marzia Monica Giuliani
Vega Masignani
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of SG10201900041VA publication Critical patent/SG10201900041VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

MENINGOCOCCUS VACCINES Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose. 5 (No drawing to be published)
SG10201900041VA 2014-07-17 2015-07-16 Meningococcus vaccines SG10201900041VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177563 2014-07-17

Publications (1)

Publication Number Publication Date
SG10201900041VA true SG10201900041VA (en) 2019-02-27

Family

ID=51178811

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201900041VA SG10201900041VA (en) 2014-07-17 2015-07-16 Meningococcus vaccines
SG11201610946YA SG11201610946YA (en) 2014-07-17 2015-07-16 Meningococcus vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610946YA SG11201610946YA (en) 2014-07-17 2015-07-16 Meningococcus vaccines

Country Status (15)

Country Link
US (2) US11707513B2 (en)
EP (1) EP3169358A1 (en)
JP (2) JP6687597B2 (en)
KR (2) KR20230012100A (en)
CN (2) CN113827712A (en)
AR (2) AR101225A1 (en)
AU (2) AU2015289193A1 (en)
BE (1) BE1022878B1 (en)
BR (1) BR112017000519A2 (en)
CA (1) CA2954729C (en)
EA (1) EA038940B1 (en)
IL (1) IL249823B (en)
MX (1) MX2017000775A (en)
SG (2) SG10201900041VA (en)
WO (1) WO2016008961A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034954B1 (en) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са MODIFIED MENINGOCOCCAL fHbp POLYPEPTIDES
AU2015289192A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Modified meningococcal fHbp polypeptides
CN113827712A (en) 2014-07-17 2021-12-24 葛兰素史密丝克莱恩生物有限公司 Meningococcal vaccines
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
CN107961370B (en) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 Multivalent pneumococcal conjugate vaccine and preparation method thereof
CN108939061A (en) * 2018-08-03 2018-12-07 北京智飞绿竹生物制药有限公司 A kind of multicomponent B group meningitis cocci vaccine and preparation method thereof
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11014736B2 (en) 2019-04-18 2021-05-25 Altria Client Services Llc Sliding packs with flip top hinged lids
CN110804101A (en) * 2019-11-08 2020-02-18 苏州微超生物科技有限公司 Group B meningococcus related fusion protein, vaccine, preparation method and application thereof
CA3162559A1 (en) * 2019-11-25 2021-06-03 Griffith University Immunogenic protein against gonococcal infection
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
WO2025077785A1 (en) * 2023-10-10 2025-04-17 康希诺生物股份公司 Anti-neisseria meningitidis immune composition and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP2275129A3 (en) * 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
CN102917730A (en) 2009-10-27 2013-02-06 诺华有限公司 Modified meningococcal fHBP polypeptides
WO2011110634A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
CN110845585A (en) 2010-03-30 2020-02-28 奥克兰儿童医院及研究中心 Modified Factor H Binding Proteins (FHBP) and methods of use thereof
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
US10376573B2 (en) * 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EA034954B1 (en) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са MODIFIED MENINGOCOCCAL fHbp POLYPEPTIDES
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
AU2015289192A1 (en) 2014-07-17 2017-02-02 Glaxosmithkline Biologicals S.A. Modified meningococcal fHbp polypeptides
CN113827712A (en) 2014-07-17 2021-12-24 葛兰素史密丝克莱恩生物有限公司 Meningococcal vaccines
CA3103741A1 (en) 2018-06-21 2019-12-26 Basf Se 3-phenyl-benzofuran-2-one diphosphate derivatives as stabilizers

Also Published As

Publication number Publication date
CN106659776A (en) 2017-05-10
KR20170029615A (en) 2017-03-15
CN113827712A (en) 2021-12-24
US20230414736A1 (en) 2023-12-28
KR102626831B1 (en) 2024-01-22
AR130778A2 (en) 2025-01-15
AU2019201131C1 (en) 2021-03-18
BE1022878A1 (en) 2016-09-30
BE1022878B1 (en) 2016-09-30
CA2954729C (en) 2023-08-22
EA201692554A1 (en) 2017-07-31
US12485164B2 (en) 2025-12-02
IL249823A0 (en) 2017-03-30
AU2019201131A1 (en) 2019-03-07
JP7074793B2 (en) 2022-05-24
KR20230012100A (en) 2023-01-25
US11707513B2 (en) 2023-07-25
MX2017000775A (en) 2017-05-04
IL249823B (en) 2022-07-01
AR101225A1 (en) 2016-11-30
JP2017522319A (en) 2017-08-10
JP2020117523A (en) 2020-08-06
BR112017000519A2 (en) 2017-11-21
SG11201610946YA (en) 2017-01-27
US20180214531A1 (en) 2018-08-02
AU2015289193A1 (en) 2017-02-02
EP3169358A1 (en) 2017-05-24
JP6687597B2 (en) 2020-04-22
CA2954729A1 (en) 2016-01-21
AU2019201131B2 (en) 2020-08-27
WO2016008961A1 (en) 2016-01-21
EA038940B1 (en) 2021-11-12

Similar Documents

Publication Publication Date Title
SG10201900041VA (en) Meningococcus vaccines
ZA202004557B (en) Modulatory polynucleotides
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
IL267346A (en) Virulence attenuated bacteria based protein delivery
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX2019007020A (en) Il-11 antibodies.
SG10201803042PA (en) Anti-tim-3 antibodies
IL255589B (en) Compounds targeting proteins, compositions, methods, and uses thereof
MY187540A (en) Compounds active towards bromodomains
EP3303382A4 (en) Compositions and methods for treating patients with rtk mutant cells
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
TW201613966A (en) SynTac polypeptides and uses thereof
MX2019007021A (en) Il-11ra antibodies.
MY191581A (en) Anti-pd-1 antibodies
MX384192B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EP3604535A3 (en) Methods and compositions for weed control
MY191539A (en) Streptococcal vaccine
MX2018000715A (en) Methods for treating cancer using apilimod.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2014009750A (en) Antifungal compositions for the treatment of skin and nails.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
NZ721832A (en) Solid forms of tenofovir
WO2016077580A3 (en) Compositions and methods for treating melanoma